Narayana Hrudayalaya Ltd. (NH)

Healthcare · Healthcare Services · NSE · Updated 15 July 2026

₹2,037.4 ↑ 2.67% (1Y)

🎯 Key Takeaways

Narayana Hrudayalaya Ltd. is in a strategic expansion and margin improvement phase, transitioning from a high-growth hospital builder to a scalable healthcare services platform with international ambitions.
Revenue declined 2.4% QoQ to ₹1,367 in Q3FY25.
⚠️ International operations, particularly in the UK and future expansions, remain cash-intensive with no clear path to near-term profitability, posing ex

Market Cap

₹37,625

P/E Ratio

47.7

Div Yield

0.00%

Promoter

0.0%

✨ Ask AI About NH 📊 Interactive Charts

📖 The Story

Narayana Hrudayalaya Ltd. is in a strategic expansion and margin improvement phase, transitioning from a high-growth hospital builder to a scalable healthcare services platform with international ambitions. Management is prioritizing revenue growth through clinic expansion and technology adoption, while accepting short-term clinic losses to accelerate scale. The company maintains strong governance discipline and consistent dividend policy, signaling financial stability despite elevated valuation multiples.

📰 What's Happening

In Q4 FY26, management reported 69.9% YoY revenue growth to ₹1,327 crores, driven by hospital expansion and technology adoption, alongside a 400 basis point OPM expansion to 25.1%. Clinic losses widened to ₹66 crores due to new openings, particularly in emerging markets like Calcutta. UK operations improved EBITDA margins to 10% but remain insufficient for loan repayment. Management reiterated plans to double clinic count by FY27, enter new geographies, and implement 30-35% price increases in the Cayman insurance business to drive profitability. A final dividend of ₹4.50 per share was recommended, with shareholders required to submit tax documents by July 24, 2026, to optimize net receipts.

Source: Stock Announcements

📊 Quarterly Results (₹ Cr)

Metric	Q4FY23	Q1FY24	Q2FY24	Q3FY24	Q4FY24	Q1FY25	Q2FY25	Q3FY25
Revenue	1,222	1,233	1,305	1,204	1,279	1,341	1,400	1,367
Operating Profit	290	286	327	297	318	327	332	325
OPM %	22.6%	21.9%	23.6%	23.2%	23.0%	22.7%	22.0%	22.5%
Net Profit	173	184	227	188	191	201	199	193
EPS	₹8.53	₹9.06	₹11.16	₹9.26	₹9.39	₹9.92	₹9.78	₹9.50

Revenue growth has moderated slightly in recent quarters, with Q3FY25 revenue at ₹1,367 crores showing a sequential slowdown from Q2FY25’s ₹1,400 crores, but still up sharply YoY from ₹1,204 crores in Q3FY24. Net profit has stabilized around ₹190–193 crores, with EPS hovering near ₹9.5, indicating margin discipline despite volume growth. OPM has remained relatively stable in the low-22% range, with a temporary expansion to 25.1% in Q4 FY26 attributed to scale efficiencies. The company absorbed clinic losses to fuel expansion, reflecting a capital-intensive growth model focused on long-term market share gains over near-term profitability.

🔮 Management Outlook & What's Next

Management expressed confidence in sustaining growth through clinic network expansion, geographic diversification into Calcutta, and AI-driven operational efficiencies across radiology and clinical workflows. They highlighted targeted 30–35% price increases in the Cayman insurance segment to improve margins and achieve a consolidated EBITDA margin of ~20% over the next few years. Capex plans for FY28 remain unchanged despite election-related delays, with emphasis on disciplined investment and long-term structural profitability. No major M&A was announced, but the incorporation of a new subsidiary signals ongoing strategic structuring for future scalability.

Extracted from official company announcements. Not StockFin.ai's opinion.

⚖️ Peer Comparison — Healthcare Services

Company	MCap (₹ Cr)	P/E	ROCE	ROE	D/E
Apollo Hospitals Enterprise Limited	1.16 L Cr	64.5	20.5%	21.9%	0.64
Max Healthcare Institute Limited	1.02 L Cr	101.2	—	—	—
Fortis Healthcare Limited	72,752	94.6	—	—	—
Aster DM Healthcare Limited	39,048	7.1	—	—	—
Narayana Hrudayalaya Ltd.	37,625	47.7	—	—	—
Global Health Limited	33,405	65.8	—	—	—
Krishna Institute of Medical Sciences Limited	30,477	80.3	—	—	—
Dr. Lal Path Labs Ltd.	26,871	63.6	—	—	—
Syngene International Limited	18,295	36.3	—	—	—
Dr. Agarwal's Health Care Limited	14,266	88.8	14.9%	6.8%	0.13

🔗 Peer Stock Analyses

APOLLOHOSP MAXHEALTH FORTIS ASTERDM MEDANTA

⚠️ Risk Factors

1. International operations, particularly in the UK and future expansions, remain cash-intensive with no clear path to near-term profitability, posing execution and capital allocation risks. 2. Clinic losses are widening due to aggressive expansion, which could pressure near-term earnings if revenue growth slows or patient acquisition falters. 3. Margin gains from scale and pricing increases in the insurance segment are critical but unproven at scale; failure to convert volume into sustainable profitability could undermine the growth thesis. 4. Regulatory and compliance vigilance is heightened, as evidenced by insider trading window restrictions, introducing operational friction around earnings announcements.

📋 Recent Filings

🧠 Analyst's Read

Narayana Hrudayalaya is executing a capital-intensive expansion strategy with improving operational metrics but persistent clinic losses and delayed path to international profitability. Management’s long-term vision is coherent, but near-term financials reflect investment over earnings. Investors should monitor clinic ramp-up speed, UK unit cash burn, and the pace of margin improvement from pricing and efficiency initiatives as key near-term catalysts.

Based on filing content and financial data. Not a recommendation.

Read the full analysis

Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.

2 free AI queries per day.

✨ Deep Dive with AI on NH

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-07-15.

📡 Get AI alerts when NH files new disclosures

Track NH filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track NH — Free

Free account · 2 AI queries/day